$2.12
+0.06 (+2.91%)
VERU News2 articles
Veru Stock Soars on Novo Nordisk Supply Deal for Obesity Trial
Veru shares jumped 88% to $4.23 after Novo Nordisk agreed to supply Wegovy for Veru's Phase 2b obesity trial. Analysts see it as a validation, but risks remain with trial endpoints and a 60-day exit clause.
Veru Stock Surges on Novo Nordisk Obesity Trial Collaboration
Veru shares surged 112% to $4.78 after Novo Nordisk will provide Wegovy for Veru's Phase 2b obesity trial. Analysts kept $24-$25 targets, but Veru warned of trial risks and reimbursement challenges.